Prevention of Organ Transplant Rejection: Current Therapies and Novel StrategiesDecision ResourcesSeptember 14, 2005 14 Pages - SKU: DECR1212091 |
|
Out-of-Pocket Healthcare 2012
4/3/2012 | published by: Kalorama Information
Despite numerous attempts to reign in costs of healthcare, consumers are increasingly paying for healthcare products and services from their own monies. The costs of health care products and services continue
|
more...
|
$995.00
|
|
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors
|
more...
|
$3,995.00
|
|
Canada Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: With Canada’s economy set to weather the external storm, the outlook for the country’spharmaceutical market looks relatively stable. Over the longer-term an ageing population in this alreadymature market should support spending. We also
|
more...
|
$1,175.00
|
|
Kuwait Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: While Kuwait will continue to be of interest to multinational drugmakers – on account oftraditional preference for branded medicines and the population’s wealth – we caution that strengtheningregional harmonisation will make for an
|
more...
|
$1,175.00
|
|
Spain Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: Companies with significant exposure to debt-ridden European markets will be hard hit bygovernment austerity measures across the region, particularly by pharmaceutical price erosionmechanisms. The Spanish government’s austerity measures look set to continue to
|
more...
|
$1,175.00
|
|
West and Central Africa Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: The better regulated markets of the Gulf Cooperation Council (GCC), South Africa and Israelwill remain the most rewarding and least risky for drugmakers operating in the Middle East and Africa(MEA). However, these markets
|
more...
|
$1,175.00
|
|
China Pharmaceutical Industry Research and Forecast to 2016
3/1/2012 | published by: AM Mindpower Solutions
EXECUTIVE SUMMARY The present report on “China Pharmaceutical Industry Research and Forecast to 2016” analyzes in detail the pharmaceutical industry environment with market sizing in terms of patented drugs, generic drugs, OTC drug and even sub-segments
|
more...
|
$700.00
|
|
Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates
2/29/2012 | published by: GBI Research
Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates Summary GBI Research’s new report, “Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates”
|
more...
|
$3,500.00
|
|
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation
2/29/2012 | published by: GlobalData
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation Summary The report is an essential source of information and analysis on the KALYDECO (ivacaftor, VX-770) for the treatment of Cystic Fibrosis (CF) patients with
|
more...
|
$500.00
|
|
Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report
3/21/2012 | published by: IBISWorld
Brand Name Pharmaceutical Manufacturing in the US Prescription for growth With healthcare reform allowing more individuals to gain prescription coverage, brand-name pharmaceutical and medicine manufacturers will experience a surge in demand. The expansion of biosimilar drugs will
|
more...
|
$910.00
|
